Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

JW Pharmaceutical64 enrolled

Overview

The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Gout Hyperuricemia

Interventions

URC102 0.25mgDRUG

URC102 0.5mgDRUG

URC102 1.0mgDRUG

URC102 2.0mgDRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with gout Exclusion Criteria: * Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)

Locations (1)

JW Pharmaceutical

Seoul, Seocho-dong, South Korea

Outcomes

Primary Outcomes

Trend of serum uric acid reduction and trend of serum uric acid levels

Frequency of patients with serum uric acid level reduced to \< 6.0 mg/dL and \< 5.0 mg/dL at each measurement

Time frame: weekly for 3weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.